Montelukast Sodium - CAS 151767-02-1
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Leukotriene Receptor
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
Publictions citing BOC Sciences Products
  • >> More
1.A Validated LC Method for Determination of the Enantiomeric Purity of Montelukast Sodium in Bulk Drug Samples and Pharmaceutical Dosage Forms
P. Radhakrishnanand, D. V. Subba Rao. Chromatographia 2008, 68, August (No. 3/4)
A few analytical methods had been reported in the literature for determination of montelukast sodium in human plasma by column-switching HPLC with fluorescence detection. Liu et al. separated the enantiomers of montelukast from human plasma by use of column-switching with fluorescence detection, but the injection procedure was a laborious and time-consuming process. As far as we are aware no enantioselective HPLC methods have been reported in the literature for determination of the enantiomeric purity of montelukast sodium or accurate quantification of the impurity, i.e. the S enantiomer, in bulk drugs and pharmaceutical formulations. This paper deals with the development and validation of a method for determination of the enantiomeric purity of montelukast sodium.
2.Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats
Dong Wuk Kim • Young Hun Kim • Abid Mehmood Yousaf. Arch. Pharm. Res. (2016) 39:539–546
Various stabilizers (62.4 mg) were added in 100 ml of the suspensions containing 312 mg montelukast sodium and 2496 mg Avicel (Fig. 2). As shown in Fig. 2a, the suspension without stabilizer was given approximately 1.8 % montelukast sulphoxide and demonstrated the sedimentation phenomenon at 2 months. The suspension with sodium pyrosulphate presented \1 % montelukast sulphoxide, but it induced sedimentation at 2 months. The suspensions with sodium thiosulfate and propyl gallate exhibited [1 % degradation product, and induced sedimentation at 2 months. Moreover, the suspension with fumaric acid resulted in \1 % degradation product and total impurities at 2 months; however, the sedimentation took place. Additionally, different quantities of fumaric acid (3.12–62.4 mg) were transferred to 100 ml of the montelukast sodium (312 mg)-loaded suspensions, and their stabilities were evaluated (Fig. 3). As the amounts of fumaric acid were increased, the concentrations of degradation product were reduced.
3.pKa Determinations for Montelukast Sodium and Levodropropizine
Ibrahim Narin, Salih Sarioglan, Beril Anilanmert, Hayati Sari. J Solution Chem (2010) 39: 1582–1588
Acid dissociation constant determination studies have been performed for drugs like epirubicin·HCl and irinotecan·HCl, cefetamet and many other drugs used as antiinflammatories, antibiotics, β-blockers, etc. Mixed solvents were used for some of these drug studies, because of solubility problems in water at the concentrations used in the experiments. In this study, the pKa constants of Montelukast sodium and Levodropropizine were determined potentiometrically using the Irving–Rossotti method. Relative abundances of the ionized and unionized species were calculated at various pHs.
4.Novel montelukast sodium-loaded clear oral solution prepared with hydroxypropyl-b-cyclodextrin as a solubilizer and stabilizer: enhanced stability and bioequivalence to commercial granules in rats
Young Hun Kim • Dong Wuk Kim • Min Seok Kwon. J Incl Phenom Macrocycl Chem (2015) 82:479–487
Various amounts of solubilizers, preservatives and EDTA sodium were completely dissolved in 100 ml distilled water. Soluplus, Kolliphor, PVP and HP-b-CD were used as solubilizers. Methylparaben sodium and propylparaben sodium were used as preservatives. Then, montelukast sodium was added into these solutions and stirred for 1 h, leading to the montelukast sodium-loaded oral solutions. The drug solubility and stability tests were carried out with these solutions as mentioned below.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Leukotriene Receptor Products

CAS 111130-13-3 Cgp-35949

(CAS: 111130-13-3)

Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.

CAS 148291-65-0 LY 210073

LY 210073
(CAS: 148291-65-0)

LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...

CAS 117690-79-6 LY255283

(CAS: 117690-79-6)

This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...

CAS 118414-82-7 MK-886

(CAS: 118414-82-7)

This active molecular is a leukotriene antagonist with the IC50 of 3 nM in human polymorphonuclear leukocytes. MK-886 also inhibits PPARα activation. Inhibition...

(CAS: 103176-67-6)

Ono-RS-347 is an SRS-A antagonist and a new leukotriene antagonists.

(CAS: 111130-14-4)

Cgp-33304 is a dual phospholipase A2 inhibiting agent and leukotriene receptor antagonists. It may prevent hypoxia secondary to leukotriene induced bronchoconst...

CAS 113806-05-6 Olopatadine

(CAS: 113806-05-6)

This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...

CAS 154355-76-7 Atreleuton

(CAS: 154355-76-7)

Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...

(CAS: 104448-53-5)

ICI-198615 is a novel, potent and selective peptide leukotriene antagonist. It may be useful for the the treatment of allergic diseases.

LY 213024
(CAS: 117423-95-7)

LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal m...

(CAS: 1232861-58-3)

This active molecular is an potent dual Leukotriene CysLT1 and CysLT2 Receptor antagonist originated by Ono Pharmaceutical. IC50 values is 1.7nM against human C...

CAS 117423-74-2 LY223982

(CAS: 117423-74-2)

This active molecular is benzophenone dicarboxylic acid derivative which is a potent BLT1 receptor antagonist. It inhibits the binding of radiolabeled-LTB4 to i...

LY 292728
(CAS: 153034-77-6)

LY 292728, an oxoxanthene derivative, has been found to be a leukotriene B4 receptor antagonist that has once been studied as an antiasthmatic agent.

CAS 943764-99-6 Acebilustat

(CAS: 943764-99-6)

Acebilustat, formerly known as ZK322, is an oral anti-inflammatory designed to reduce the production of leukotriene B4 (LTB4),.

(CAS: 158103-57-2)

CP-195494, a benzothiazol derivative, was once studied as a leukotriene receptor antagonist.

(CAS: 107889-31-6)

LY-25648 is a leukotriene B4 antagonist.

(CAS: 134578-96-4)

ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trial...

LY 203647
(CAS: 122009-61-4)

LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...

(CAS: 158081-99-3)

CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.

CAS 99107-52-5 U66858

(CAS: 99107-52-5)

U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.

Chemical Structure

CAS 151767-02-1 Montelukast Sodium

Quick Inquiry

Verification code

Featured Items